Antif i brotic Effect of a Novel Selective11β-HSD2 Inhibitor (WZ51) in a ratModel of Myocardial FibrosisFei Zhuang 1 , 2 , 3 , Qin Ge 4 , Jianchang Qian 5 , Zhe Wang 1 , Yaoyao Dong 1 , Mengchun Chen 1 ,Xiaodan Zhang 3 * and Wei Sun 1 *1 Department of Pharmacy, The S...
Adverse Events of Pirfenidone for the Treatment of Pulmonary Fibrosis: A Meta-Analysis of Randomized Controlled Trials Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. ......
The applications of a specific collagen type I inhibitor as an antifibrotic drug are practically unlimited, because any perturbation in the cellular function of any tissue may cause excessive collagen deposition. Inhibition of collagen type I synthesis on the transcriptional level might be more effective...
SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis (vol 195, pg 500, 2017) The correction to the article "SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis." published in February 15, 2017... A Tzouvelekis,G ...
the antifibrotic effect of theβ-blockade was most obvious. The transcript levels of procollagen 1A1, TNF-α, TGF-β, CTGF and endothelin-1 were markedly repressed in the portal areas of treated mice. Taken together, these data show that propranolol efficiently delays progression of sclerosing ch...
Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-β soluble receptor: Implications for antifibrotic therapy Transforming growth factor (TGF) β isoforms (in particular, TGF-β1) play a central role in the fibrogenic response to injury in many organs, including the liver. Although ...
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate 来自 semanticscholar 喜欢 0 阅读量: 103 作者: Boubia, Benaissa,Poupardin, Olivia,...
intimal hyperplasia is mediated by smooth muscle cell proliferation, migration and deposition of extracellular matrix. The anti-fibrotic agent pirfenidone has been shown to inhibit pro-fibrotic growth factors in non-vascular inflammatory models. This study investigated the effect of the novel anti-fibroti...
conducted in Japanese patients with well-defined IPF to determine the efficacy and safety of pirfenidone, a novel antifibrotic oral agent, over 52 weeks. ... Swigris, J.,Fairclough, D. - 《European Respiratory Journal》 被引量: 1836发表: 2010年 Pirfenidone in idiopathic pulmonary fibrosis Idiop...
Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant Proceed. 1998;30:1910-1... A.K Dosanjh a,B Wan a,W Throndset a,... - 《Transplantation Proceedings》 被引量: 35发表: 1998年 Pirfenidone in idiopathic pulmonary fibrosis conducted...